A Malvern biotechnology company, Aclaris Therapeutics, said Monday it filed a new drug application with the Food and Drug Administration to approve its hydrogen peroxide topical treatment for noncancerous skin growths in the United States. The skin condition, seborrheic keratosis, affects more than 83 million Americans.
If approved, the topical solution, which is administered in a physician's office, would be the first FDA-approved topical treatment. Existing treatments include freezing the growth, using liquid nitrogen, or scraping it off which can cause scarring and changes in skin color, the company said. The growths often appear on the face, chest, shoulders, or back and have a waxy, scaly, slightly elevated appearance that can vary in color from light tan to dark brown or black.
Aclaris is pursuing additional dermatological uses for the investigational drug, referred to as A-101, such as treatment of common warts. The company was founded in 2012 to develop medicines for dermatological conditions.